According to the Journal Citation reports from Clarivate Analytics (2021), Gynecologic Oncology’s 2020 Impact Factor has increased from 4.62 (2019) to 5.48 (2020). The journal is now positioned 79 out of 242 in the category of Oncology and 8 out of 82 in the category of Obstetrics & Gynecology!
This is the first time that the journal has exceeded a 5.0 score. “As editor-in-chief, I was thrilled to see Gynecologic Oncology’s 2020 impact factor rise to 5.482—placing us in the top 10% of all ob/gyn journals and in the top third of all oncology journals,” says Beth Y. Karlan, MD.
“This growth would not have been possible without the high quality manuscripts submitted by our dedicated authors and expert peer review by our reviewers, editorial board members and editors. Gynecologic Oncology is the official publication of the SGO, so as past-president of the Society, this achievement made me especially proud of our members and our long standing partnership,” said Dr. Karlan.
Gynecologic Oncology Reports has also now been included in the Obstetrics & Gynecology Category within the Emerging Sources Citation Index (ESCI), which is a great step forward towards evaluation for an Impact Factor.
Further, Clarivate has released a new Journal Citation Indicator (JCI), that calculates the Category Normalized Citation Impact (CNCI) of citable items (articles & reviews) published over a 3 year period (more info here). Gynecologic Oncology has a JCI of 1.48, indicating that 48% of content is more cited than the average for the category, and Gynecologic Oncology Reports has a JCI of 0.48. Within the Obstetrics & Gynecology category the journals hold JCI rankings of 9/121 and 88/121, respectively.